Blood Res 2016; 51(1):
Published online March 31, 2016
https://doi.org/10.5045/br.2016.51.1.31
© The Korean Society of Hematology
1Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
2Division of Radiation Effect, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
3Laboratory Animal Facility, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Correspondence to : Correspondence to Jun Ah Lee, M.D., Ph.D. Department of Pediatrics, Korea Cancer Center Hospital, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. junahlee@kcch.re.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Humanized mouse models are still under development, and various protocols exist to improve human cell engraftment and function.
Fourteen NOD/SCID/IL-2Rγnull (NSG) mice (4‒5 wk old) were conditioned with busulfan and injected with human umbilical cord blood (hUCB)-derived CD34+ hematopoietic stem cells (HSC) via retro-orbital sinuses. The bone marrow (BM), spleen, and peripheral blood (PB) were analyzed 8 and 12 weeks after HSC transplantation.
Most of the NSG mice tolerated the regimen well. The percentage of hCD45+ and CD19+ cells rose significantly in a time-dependent manner. The median percentage of hCD45+cells in the BM was 55.5% at week 8, and 67.2% at week 12. The median percentage of hCD45+ cells in the spleen at weeks 8 and 12 was 42% and 51%, respectively. The median percentage of hCD19+ cells in BM at weeks 8 and 12 was 21.5% and 39%, respectively (
We adopted a simplified protocol for establishing humanized NSG mice. We observed a higher engraftment rate of human CD45+ cells than earlier studies without any significant toxicity. And human CD45+ cell engraftment at week 8 was comparable to that of week 12.
Keywords Humanized mice, Busulfan, Retro-orbital sinus, Hematopoietic stem cell
Blood Res 2016; 51(1): 31-36
Published online March 31, 2016 https://doi.org/10.5045/br.2016.51.1.31
Copyright © The Korean Society of Hematology.
Young Kyung Kang1,#, Yunmi Ko1,#, Aery Choi1, Hyeong Jwa Choi2, Jin-Hee Seo3, Minyoung Lee2,3, and Jun Ah Lee1*
1Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
2Division of Radiation Effect, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
3Laboratory Animal Facility, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Correspondence to: Correspondence to Jun Ah Lee, M.D., Ph.D. Department of Pediatrics, Korea Cancer Center Hospital, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. junahlee@kcch.re.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Humanized mouse models are still under development, and various protocols exist to improve human cell engraftment and function.
Fourteen NOD/SCID/IL-2Rγnull (NSG) mice (4‒5 wk old) were conditioned with busulfan and injected with human umbilical cord blood (hUCB)-derived CD34+ hematopoietic stem cells (HSC) via retro-orbital sinuses. The bone marrow (BM), spleen, and peripheral blood (PB) were analyzed 8 and 12 weeks after HSC transplantation.
Most of the NSG mice tolerated the regimen well. The percentage of hCD45+ and CD19+ cells rose significantly in a time-dependent manner. The median percentage of hCD45+cells in the BM was 55.5% at week 8, and 67.2% at week 12. The median percentage of hCD45+ cells in the spleen at weeks 8 and 12 was 42% and 51%, respectively. The median percentage of hCD19+ cells in BM at weeks 8 and 12 was 21.5% and 39%, respectively (
We adopted a simplified protocol for establishing humanized NSG mice. We observed a higher engraftment rate of human CD45+ cells than earlier studies without any significant toxicity. And human CD45+ cell engraftment at week 8 was comparable to that of week 12.
Keywords: Humanized mice, Busulfan, Retro-orbital sinus, Hematopoietic stem cell
Scheme for generating the humanized NSG mice. MNCs isolated from hUCB were enriched using a RosetteSep kit and human CD34 MicroBead Kit. NSG mice were conditioned by busulfan and CD34+ cells were injected via retro-orbital sinus.
Survival and weight changes of the NSG mice after hCD34+ cell injection. Humanized NSG mice were monitored daily after transplantation. Most of the NSG mice did well, but one mice (depicted with an arrow) showed features suggesting GVHD (weight loss, hunched posture and diminished activity as shown in the photo) 10 days after transplantation.
Human cell reconstitution of NSG mice transplanted with hUCB-derived CD34+ cells. Levels of human CD45+ cells in mouse tissues at different times after transplantation are shown. Bone marrow, spleen, and blood were isolated from the humanized NSG mice and MNCs isolated from each organ were stained and analyzed. The percentages are represented as mean±SEM in humanized mice.
Human CD19+ and CD3+ cell reconstitution from NSG mice injected with hUCB-derived CD34+ cells. The percentages are represented by mean±SEM in humanized mice.
hCD45 and hCD7 expression levels in spleen (SPL) and bone marrow (BM) of NSG mice 8 weeks after hUCB-derived CD34+ cell injection.
Ja Min Byun, Jayoun Lee, Sang-Jin Shin, Minjoo Kang, Sung-Soo Yoon, and Youngil Koh
Blood Res 2018; 53(2): 105-109Ji Hyun Lee, Jimin Choi, Kyung A Kwon, Suee Lee, Sung Yong Oh, Hyuk-Chan Kwon, Hyo-Jin Kim, Jin Yeong Han, and Sung-Hyun Kim
Korean J Hematol 2010; 45(2): 102-108Young Ho Lee, Yeon Jung Lim
Korean J Hematol 2008; 43(4): 203-218
Scheme for generating the humanized NSG mice. MNCs isolated from hUCB were enriched using a RosetteSep kit and human CD34 MicroBead Kit. NSG mice were conditioned by busulfan and CD34+ cells were injected via retro-orbital sinus.
|@|~(^,^)~|@|Survival and weight changes of the NSG mice after hCD34+ cell injection. Humanized NSG mice were monitored daily after transplantation. Most of the NSG mice did well, but one mice (depicted with an arrow) showed features suggesting GVHD (weight loss, hunched posture and diminished activity as shown in the photo) 10 days after transplantation.
|@|~(^,^)~|@|Human cell reconstitution of NSG mice transplanted with hUCB-derived CD34+ cells. Levels of human CD45+ cells in mouse tissues at different times after transplantation are shown. Bone marrow, spleen, and blood were isolated from the humanized NSG mice and MNCs isolated from each organ were stained and analyzed. The percentages are represented as mean±SEM in humanized mice.
|@|~(^,^)~|@|Human CD19+ and CD3+ cell reconstitution from NSG mice injected with hUCB-derived CD34+ cells. The percentages are represented by mean±SEM in humanized mice.
|@|~(^,^)~|@|hCD45 and hCD7 expression levels in spleen (SPL) and bone marrow (BM) of NSG mice 8 weeks after hUCB-derived CD34+ cell injection.